Purple Biotech (PPBT) Current Assets (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Current Assets data on file, last reported at $6.8 million in Q1 2026.

• On a quarterly basis, Current Assets fell 9.79% year-over-year to $6.8 million in Q1 2026; TTM through Mar 2026 was $6.8 million, a 9.79% decrease from a year earlier, with the FY2025 full-year figure at $9.9 million, up 10.75% from the prior year.
• Current Assets for Q1 2026 stood at $6.8 million, down from $9.9 million in the prior quarter.
• Over the last five years, Current Assets for PPBT reached as high as $41.9 million in Q1 2022 and fell as low as $6.3 million in Q2 2025.
• Historically, Current Assets has averaged $17.6 million across 5 years, with a median of $11.4 million in 2024.
• Across the five-year window, Current Assets tumbled 59.43% in 2024 and surged 55.29% in 2025, its largest moves.
• Year by year, Current Assets stood at $33.3 million in 2022, then tumbled by 52.53% to $15.8 million in 2023, then tumbled by 43.58% to $8.9 million in 2024, then grew by 10.75% to $9.9 million in 2025, then slumped by 31.29% to $6.8 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $6.8 million in Q1 2026, $9.9 million in Q4 2025, and $10.8 million in Q3 2025.